
As an Amazon Associate and affiliate partner, Menrva Books earns from qualifying purchases. Learn more
In collaboration with Consulting Editor Dr. Helen Boucher, Drs. Aruna Subramanian and Dora Yuk-Wai Ho have created an extremely timely and relevant issue for infectious disease physcians, as the field of biologics is exploding. These new agents are being used in rheumatologic diseases, hematologic malignancies, solid tumors, and other conditions; there is a lack of guidance in the literature on how to address their infectious risks. The first 9 articles explain the mechanisms of action of the biologic agents and the infectious disease risks associated with their immune system targets. The last few articles go into more depth on the viral, fungal, and mycobacterial infections that are potentiated by biologics, and discuss recommended prophylaxis and preventative strategies, including vaccinations. Specifically, articles are devoted to the following: TNF inhibitors; Agents targeting B cells; Agents targeting T cell activation; Direct T cell inhibition and agents targeting T cell migration and chemotaxis; IL-1 and IL-6 and other interleukin and IgE inhibition; Check-point inhibitors; Tyrosine kinase inhibitors for heme malignancies; EGFR inhibitors and other Tyrosine kinase inhibitors for solid tumors; Targeting JAK-STAT signaling and complement pathway for inflammatory diseases; Viral infections Potentiated by Biologics (and Prophylaxis); Endemic Fungal Infections Potentiated by Biologics (and prophylaxis); Mycobacterial Infections Potentiated by Biologics; and Vaccinations for patients on biologics. Readers will come away with the clinical overviews of these topics to improve prevention and management of patients treated with biologics.
The increasing use of biologic agents in medicine presents a significant challenge in managing the associated infectious risks. This issue of Infectious Disease Clinics of North America, edited by Drs. Aruna Subramanian and Dora Ho, addresses the critical need for guidance on the infectious complications arising from these powerful new therapies. The articles explore the mechanisms of action of various biologics, detail the specific infectious disease risks linked to their targets within the immune system, and provide in-depth discussions on viral, fungal, and mycobacterial infections potentiated by these agents. Recommended prophylaxis, preventative strategies, and vaccinations for patients receiving biologics are also thoroughly examined, offering clinicians essential overviews for improved patient care.
This compilation is designed to provide infectious disease physicians with essential clinical overviews regarding the management of patients treated with biologics. The focus on the exploding field of biologics and the associated lack of literature guidance makes this a timely resource. The structured approach, detailing mechanisms, risks, and specific infection types, aims to equip readers with improved prevention and management strategies. The inclusion of prophylaxis and vaccination recommendations further enhances its practical utility for clinicians.
Page Count:
240
Publication Date:
2020-06-04
Publisher:
Elsevier Health Sciences
ISBN-10:
0323733204
ISBN-13:
9780323733205
No comments yet. Be the first to share your thoughts!